HDAC9 and neuroblastoma: Short chain fatty acids (VPA, 2 μM), hydroxyamic acids (TSA, 500 nM and SAHA, 1 μM) and synthetic benzamide derivatives (M344, 1 μM), all inhibitors of HDAC, transcriptionally decreased c-Jun/MEK1/2-ERK1/2, FRA1, and Raf decreased the cell viability of neuroblastoma cell lines SH-SY5Y and SK-N-SH; these results suggest the potential use of HDAC inhibitors as therapeutics [77].